Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat–Fed Mice
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE— We examined whether chronic administration of a glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 (Ex-4), a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist d-Ala2-GIP (DA-GIP), or a dipeptidyl peptidase-4 (DPP-4) inhibitor (DPP-4i) des-fluoro-sitagliptin produced comparable antidiabetic actions in high fat–fed mice. RESEARCH DESIGN AND METHODS— High fat–fed mice were administered twice-daily injections of Ex-4, DA-GIP, vehicle (saline), or vehicle with the addition of des-fluoro-sitagliptin (DPP-4i) in food to produce sustained inhibition of DPP-4 activity. RESULTS AND CONCLUSIONS— Mice treated with vehicle alone or DA-GIP exhibited progressive weight gain, whereas treatment with Ex-4 or DPP-4i prevented weight gain. Although Ex-4 improved oral glucose tolerance and insulin-to-glucose ratios after an intraperitoneal glucose tolerance test (IPGTT), DPP-4i had no significant effect after IPGTT but improved glucose excursion and insulin levels after an oral glucose tolerance test. The extent of improvement in glycemic control was more sustained with continuous DPP-4 inhibition, as evidenced by loss of glucose control evident 9 h after peptide administration and a significant reduction in A1C observed with DPP-4i but not with DA-GIP or Ex-4 therapy. DA-GIP, but not Ex-4 or DPP-4i, was associated with impairment in insulin sensitivity and increased levels of plasma leptin and resistin. Although none of the therapies increased β-cell mass, only Ex-4–treated mice exhibited increased pancreatic mRNA transcripts for Irs2, Egfr, and Gck. These findings highlight significant differences between pharmacological administration of incretin receptor agonists and potentiation of endogenous GLP-1 and GIP via DPP-4 inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“The interest in the actions of these incretin hormones has increased considerably in recent years following clinical evidence suggesting that incretinbased therapies may be useful for the treatment of human subjects with type 2 diabetes (3,4).”
BackgroundSelf-citationBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“GIP receptor agonists also potentiate glucosestimulated insulin secretion, but unlike GLP-1, GIP does not appear to have significant effects on glucagon secretion, gastric emptying, or body weight (1).”
BackgroundSelf-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“GLP-1R agonists consistently produce satiety (41,42) and weight loss (3,43,44), whereas chronic administration of GIP has not been shown to reduce appetite or body weight.”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 3×
“The interest in the actions of these incretin hormones has increased considerably in recent years following clinical evidence suggesting that incretinbased therapies may be useful for the treatment of human subjects with type 2 diabetes (3,4).”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
Buteau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Self-citationNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Sauvé, M., Ban, K., Momen, M. A., Zhou, Y.-Q., Henkelman, R. M., Husain, M., & Drucker, D. J. (2010) · Diabetes · doi:10.2337/db09-0955 · Cited by 264
Self-citationShirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246
GLP-1 and energy balance: an integrated model of short-term and long-term control
Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Dobrian, A. D., Ma, Q., Lindsay, J. W., Leone, K. A., Ma, K., Coben, J., Galkina, E. V., & Nadler, J. L. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00463.2010 · Cited by 166
TCF1 links GIPR signaling to the control of beta cell function and survival
Campbell, J. E., Ussher, J. R., Mulvihill, E. E., Kolic, J., Baggio, L. L., Cao, X., Liu, Y., Lamont, B. J., Morii, T., Streutker, C. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.3997 · Cited by 142
Self-citationTargeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
“Chronic agonism achieved by (D-Ala2)GIP, a long-acting DPP4 resistance GIP analog given at 24 nmol/kg twice daily for 8 weeks, did not alter body weight, food intake, body composition, or energy expenditure in highfat fed mice [91].”
BackgroundGault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125
“As expected, N-AcGIP(Lys(37)Myr) treatment did not affect body weight or food intake corroborating other findings that GIP does not affect feeding activity [23-39, 41].”
BackgroundMusso, G., Gambino, R., Pacini, G., De Michieli, F., & Cassader, M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26720 · Cited by 107
Varol, C., Zvibel, I., Spektor, L., Mantelmacher, F. D., Vugman, M., Thurm, T., Khatib, M., Elmaliah, E., Halpern, Z., & Fishman, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401149 · Cited by 89
Timper, K., Grisouard, J., Sauter, N. S., Herzog-Radimerski, T., Dembinski, K., Peterli, R., Frey, D. M., Zulewski, H., Keller, U., Müller, B., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00100.2012 · Cited by 88
Samms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
Gut hormone GIP induces inflammation and insulin resistance in the hypothalamus
Fu, Y., Kaneko, K., Lin, H.-Y., Mo, Q., Xu, Y., Suganami, T., Ravn, P., & Fukuda, M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa102 · Cited by 38
Wean, J., Kowalsky, A. H., Laker, R., Will, S., Drucker, D. J., Rhodes, C. J., & Seeley, R. J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102074 · Cited by 28
Self-citationGLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
“In addition, pancreatic -cells could also express GIP to promote insulin secretion (42), which could be processed by PC1/3 proconvertases and then inhibit glucagon secretion.”
BackgroundInfluential
Metadata
- Authors
- Lamont, B. J., & Drucker, D. J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-01-01
- Volume
- 57
- Issue
- 1
- Pages
- 190-198
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2097008225
- Cited by
- 127
- References
- 13
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.